Strong Showing for Novel BP-Lowering Drugs in Resistant Hypertension

Aprocitentan targets the endothelin pathway, whereas baxdrostat blocks aldosterone production

Related Keywords

Australia ,Perth ,Western Australia ,Waltham ,Massachusetts ,United States ,Chicago ,Illinois ,American ,Cincor Pharma ,Nicole Lou ,Suzanne Oparil ,Mason Freeman ,Markus Schlaich ,American Heart Association ,University Of Alabama At Birmingham ,University Of Western Australia ,New England Journal ,Medpage Today ,